Thermo Fisher Scientific Inc. (TMO) reported better-than-expected quarterly results and raised its annual profit guidance, citing increasing demand for its products and services in drug development and clinical trials. The company’s laboratory products segment, which contributes over half of its total revenue, saw revenue exceed analysts’ expectations.